Stock A298380 ABL BIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

ABL Bio Inc. Stock

Equities

A298380

KR7298380007

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
22,450 KRW -1.10% Intraday chart for ABL Bio Inc. -2.60% -8.74%
Mar. 25 Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates CI
2023 ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Financials

Sales 2024 * 35B 25.48M Sales 2025 * 28B 20.38M Capitalization 1,075B 783M
Net income 2024 * -22B -16.02M Net income 2025 * -29B -21.11M EV / Sales 2024 * 30.7 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 38.4 x
P/E ratio 2024 *
-49 x
P/E ratio 2025 *
-36.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 68.91%
More Fundamentals * Assessed data

Chart ABL Bio Inc.

Dynamic Chart

Latest news about ABL Bio Inc.

Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates CI
ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
I-Mab Doses First Patient in Phase 1 Trial of TJ-CD4B to Treat Solid Tumors MT
ABL Bio Inc. Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease CI
I-Mab and ABL Bio Inc. Jointly Announce Preclinical Data of Their 4-1Bb Bispecific Antibodies At the 2021 Society for Immunotherapy of Cancer Annual Meeting CI
Compass Therapeutics, Inc. and ABL Bio Presented Clinical Trial Data for CTX-009 CI
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting CI
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody CI
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody CI
I-Mab and ABL Bio Inc. Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors CI
I-Mab and ABL Bio Inc. Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors CI
HiFiBiO Therapeutics Announces Global Strategic Partnership with ABL Bio for the Co-Development of SARS-CoV-2 Neutralizing Antibody CI
I-Mab and ABL Bio Inc. to Present Preclinical Data for Joint Bispecific CI
Genscript Biologics Enters into an Agreement with ABL Bio Inc CI
ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index CI
More news

Press releases ABL Bio Inc.

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates AQ
Biocytogen and ABL Bio enter into a collaboration to jointly develop new dual-antibody ADC drugs AQ
ABL Bio Taps into Synaffix ADC Technology AQ
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease AQ
More press releases

Quotes and Performance

1 day-1.10%
1 week-2.60%
Current month-17.16%
1 month-13.32%
3 months+5.90%
6 months+35.90%
Current year-8.74%
More quotes

Highs and lows

1 week
21 500.00
Extreme 21500
22 950.00
1 month
21 500.00
Extreme 21500
27 700.00
Current year
18 960.00
Extreme 18960
30 500.00
1 year
15 370.00
Extreme 15370
30 500.00
3 years
15 370.00
Extreme 15370
34 800.00
5 years
12 250.00
Extreme 12250
40 150.00
10 years
12 250.00
Extreme 12250
40 150.00
More quotes

Managers and Directors - ABL Bio Inc.

Managers TitleAgeSince
Sang-Hoon Lee FOU
 Founder 61 16-02-15
Jae-Cheon Lee DFI
 Director of Finance/CFO 54 -
Won-Gyu Yoo PRN
 Corporate Officer/Principal 56 -
Members of the board TitleAgeSince
Sang-Hoon Lee FOU
 Founder 61 16-02-15
Jae-Cheon Lee DFI
 Director of Finance/CFO 54 -
Dong-Yoon Kim BRD
 Director/Board Member 54 -
More insiders

ETFs positioned on ABL Bio Inc.

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.01% 4 M€ -4.41% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 117 M€ -1.55% -
More ETFs positioned on ABL Bio Inc.

Quotes

Date Price Change Volume
24-04-19 22,450 -1.10% 398,655
24-04-18 22,700 +5.58% 373,480
24-04-17 21,500 -2.49% 401,888
24-04-16 22,050 -0.90% 386,348
24-04-15 22,250 -3.47% 410,900

End-of-day quote Korea S.E., April 18, 2024

More quotes

Company Profile

ABL Bio Inc. is a company mainly engaged in the development of biopharmaceuticals. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
Sector
Biotechnology & Medical Research
Calendar
2024-05-13 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ABL BIO INC. Stock ABL Bio Inc.
-8.74% 782M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.10% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.11% 96.37B
ARGENX SE Stock argenx SE
-1.80% 21.37B
BIONTECH SE Stock BioNTech SE
-17.75% 20.92B
GENMAB A/S Stock Genmab A/S
-6.91% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.4B
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.19% 13.53B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.90% 10.85B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-23.23% 8.4B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A298380 Stock